COVID-19 presentations range from cold-like symptoms to severe symptoms with the development of acute respiratory distress syndrome (ARDS). We report on a severe COVID-19 patient who was mechanically ventilated and who developed ARDS and bacterial infection. Because of rapid clinical deterioration and the exhaustion of other treatment options, the family and attending physicians requested a compassionate use of adult allogeneic bone marrow-derived mesenchymal stem cells (MSC) in addition to commonly used immunosuppressive, antiviral, and supportive therapy. The clinical course is discussed thoroughly, with a special emphasis on the safety and effect of MSC therapy. Compassionate MSC treatment, given in three rounds, affected ARDS regression. The patient was discharged from the intensive care unit after 31 days and from hospital after 49 days in a good general condition. MSC treatment was not associated with any side effects and was well tolerated in a three-week period; therefore, it should be studied in larger trials and considered for compassionate use.
【초록키워드】 COVID-19, Treatment, ARDS, therapy, Trial, intensive care, severe COVID-19, acute respiratory distress syndrome, Antiviral, hospital, intensive care unit, Mesenchymal stem cells, Clinical course, family, Patient, Exhaustion, Bacterial infection, Allogeneic, compassionate use, acute respiratory distress, MSC, immunosuppressive, stem cell, respiratory distress, attending physicians, 49 days, supportive therapy, MSC therapy, Side effect, general condition, severe symptoms, syndrome, mechanically ventilated, physician, cold-like symptoms, rapid clinical deterioration, affected, addition, discharged, severe symptom, cold-like symptom, 【제목키워드】 Treatment, severe COVID-19, Case report, Cell,